skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Index

Absorption, metabolism, and excretion of 14CMK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-4-(trifluoromethyl)phenyl methylbenzamide) in humans

Kochansky, Christopher J ; Rippley, Ronda K ; Yan, Kerri X ; Song, Hengchang ; Wallace, Michael A ; Dean, Dennis ; Jones, Allen N ; Lasseter, Kenneth ; Schwartz, Jules ; Vincent, Stella H ; Franklin, Ronald B ; Wagner, John

Drug metabolism and disposition: the biological fate of chemicals, September 2006, Vol.34(9), pp.1457-61 [Peer Reviewed Journal]

Full text available

Citations Cited by
  • Title:
    Absorption, metabolism, and excretion of 14CMK-0767 (2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-4-(trifluoromethyl)phenyl methylbenzamide) in humans
  • Author: Kochansky, Christopher J ; Rippley, Ronda K ; Yan, Kerri X ; Song, Hengchang ; Wallace, Michael A ; Dean, Dennis ; Jones, Allen N ; Lasseter, Kenneth ; Schwartz, Jules ; Vincent, Stella H ; Franklin, Ronald B ; Wagner, John
  • Description: MK-0767 (KRP-297; 2-methoxy-5-(2,4-dioxo-5-thiazolidinyl)-N-[[4-(trifluoromethyl)phenyl] methyl]benzamide) is a thiazolidinedione (TZD)-containing dual agonist of the peroxisome proliferator-activated receptors alpha and gamma that has been studied as a potential treatment for patients with type 2 diabetes. The metabolism and excretion of [14C]MK-0767 were evaluated in six human volunteers after a 5-mg (200 microCi) oral dose. Excretion of 14C radioactivity was found to be nearly equal into the urine (approximately 50%) and feces (approximately 40%). Elimination of [14C]MK-0767 was primarily by metabolism, with minimal excretion of parent compound into the urine (96% of radioactivity) through 48 h postdose. It was also found that approximately 91% of the total radioactivity area under the curve was due to intact MK-0767. Several minor metabolites were detected in plasma...
  • Is Part Of: Drug metabolism and disposition: the biological fate of chemicals, September 2006, Vol.34(9), pp.1457-61
  • Identifier: ISSN: 0090-9556 ; PMID: 16772365 Version:1
  • Subjects: Hypoglycemic Agents -- Pharmacology ; Thiazoles -- Pharmacokinetics
  • Language: English
  • Source: MEDLINE/PubMed (U.S. National Library of Medicine)

Searching Remote Databases, Please Wait